Oppenheimer Raises Price Target on Medtronic (MDT) to $94 Following EPS Beat

August 26, 2016 9:44 AM EDT
Get Alerts MDT Hot Sheet
Price: $74.99 -0.41%

Rating Summary:
    17 Buy, 19 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade MDT Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Oppenheimer reiterated an Outperform rating on Medtronic, Inc. (NYSE: MDT), and raised the price target to $94.00 (from $90.00), following the company's 1Q earnings report. MDT reported a $0.02 EPS beat, driven by a slightly lower interest expense and tax rate.

Analyst Steven Lichtman commented, "MDT delivered an in-line F1Q operationally with EPS coming in $0.02 ahead on slightly lower interest expense and tax rate. The underlying story remained the same as new product launches, emerging market expansion and hospital service offerings drove ~5%/15% constant currency constant week (CCCW) sales/EPS growth in F1Q. MDT reiterated FY17 guidance, including 5-6% CCCW sales growth and EPS of $4.60-$4.70 (12-16% CCCW). Covidien synergies are on target, and free cash flow is on track to accelerate to $6.5-7.0B in FY17. We continue to see cash flow flexibility providing upside opportunities ahead in the form of accelerated buybacks, solid dividend growth and tuck-in M&A (including the recent Heartware acquisition). MDT’s scale is another key positive in today's environment."

For an analyst ratings summary and ratings history on Medtronic, Inc. click here. For more ratings news on Medtronic, Inc. click here.

Shares of Medtronic, Inc. closed at $85.39 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Earnings, Definitive Agreement

Add Your Comment